Login Register
icon_bulk_orderBulk order Acrobiosystems for English
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > Siglec-3

Siglec-3

Brief Information

Name:Myeloid cell surface antigen CD33
Target Synonym:Myeloid Cell Surface Antigen CD33,CD33 Molecule Transcript,CD33 Antigen,Siglec-3,P67,FLJ00391,Sialic acid-binding Ig-like lectin 3,CD33,CD33 Molecule,CD33 Antigen (Gp67),SIGLEC3,Gp67,Sialic Acid Binding Ig-Like Lectin 3
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:22
Lastest Research Phase:Approved

Product ListCompare or Buy

Cat. No. Species Product Description Structure Purity Feature
CD3-HA2H6 Human Alexa Fluor 647-Labeled Human Siglec-3 / CD33 Protein, His TagStar Staining
CD3-R52H4 Rat Rat Siglec-3 / CD33 Protein, His Tag (MALS verified)
CD3-R52H4-structure
CD3-R52H4-sds
CD3-H5254 Human Human Siglec-3 / CD33 (R119G) Protein, Fc Tag
CD3-H5254-structure
CD3-H5254-sds
CD3-M52H4 Mouse Mouse Siglec-3 / CD33 Protein, His Tag
CD3-M52H4-structure
CD3-M52H4-sds
CD3-C52H4 Cynomolgus Cynomolgus Siglec-3 / CD33 Protein, His Tag
CD3-C52H4-structure
CD3-C52H4-sds
CD3-H82F3 Human Biotinylated Human Siglec-3 / CD33 Protein, Fc,Avitag™ (MALS verified)
CD3-H82F3-structure
CD3-H82F3-sds
CD3-HP2E3 Human PE-Labeled Human Siglec-3 / CD33 Protein, His Tag (Site-specific conjugation)
CD3-HP2E3-structure
MBC-K008 Human Human CD33-coupled Magnetic Beads
CD3-HF256 Human FITC-Labeled Human Siglec-3 / CD33 Protein, Fc Tag
CD3-HF256-structure
CD3-HF256-sds
CD3-HF224 Human FITC-Labeled Human Siglec-3 / CD33 Protein, His Tag
CD3-HF224-structure
CD3-HF224-sds
CD3-H5255 Human Human Siglec-3 / CD33 (18-132) Protein, Fc Tag
CD3-H5255-structure
CD3-H5255-sds
CD3-H5259 Human Human Siglec-3 / CD33 Protein, Llama IgG2b Fc Tag, low endotoxin
CD3-H5259-structure
CD3-H5259-sds
CD3-H82E7 Human Biotinylated Human Siglec-3 / CD33 Protein, Avitag™,His Tag (MALS verified)
CD3-H82E7-structure
CD3-H82E7-sds
CD3-H5257 Human Human Siglec-3 / CD33 Protein, Fc Tag (MALS verified)
CD3-H5257-structure
CD3-H5257-sds
CD3-H5226 Human Human Siglec-3 / CD33 Protein, His Tag (MALS verified)
CD3-H5226-structure
CD3-H5226-sds

Part of Bioactivity data

CD3-HP2E3-Cell-based assay
FACS assay shows that recombinant Biotinylated FACS

5e5 of anti-Siglec-3 CAR-293 cells were stained with 100 μL of 1:50 dilution (2 μL stock solution in 100 μL FACS buffer) of PE-Labeled Human Siglec-3, His Tag (Cat. No. CD3-HP2E3) and negative control protein respectively. PE signal was used to evaluate the binding activity (QC tested).

CD3-HF224-Cell-based assay
FACS assay shows that recombinant Biotinylated FACS

2e5 of anti-Siglec-3 CAR-293 cells were stained with 100 μL of 1 μg/mL of FITC-Labeled Human Siglec-3, His Tag (Cat. No.CD3-HF224) and negative control protein respectively, FITC signal was used to evaluate the binding activity (QC tested).

CD3-H5259-BLI
Human_FcRn_Heterodimer_Protein_Bli

Loaded Siglec-3 MAb (Mouse IgG1) on AMC Biosensor, can bind Human Siglec-3 Protein, Llama IgG2b Fc Tag (Cat. No. CD3-H5259) with an affinity constant of 0.365 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

CD3-H5257-BLI
Human_FcRn_Heterodimer_Protein_Bli

Loaded Siglec-3 MAb (Mouse IgG1) on AMC Biosensor, can bind Human Siglec-3, Fc Tag (Cat. No. CD3-H5257) with an affinity constant of 0.329 nM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

Customer Reviews

Synonym Name

CD33,SIGLEC3,gp67

Background

Myeloid cell surface antigen CD33 is also known as SIGLEC3, Siglecs (sialic acid binding Ig­like lectins) and GP67, is a single-pass type I membrane protein which belongs to the immunoglobulin superfamily and SIGLEC (sialic acid binding Ig-like lectin) family. Human CD33 / Siglec-3 cDNA encodes a 364 amino acid (aa) polypeptide with a hydrophobic signal peptide, an N-­terminal Ig-­like V­-type domain, one Ig­-like C2-­type domains, a transmembrane region and a cytoplasmic tail. CD33 / Siglec-3 usually considered myeloid-specific, but it can also be found on some lymphoid cells. In the immune response, CD33 / Siglec-3 may act as an inhibitory receptor upon ligand induced tyrosine phosphorylation by recruiting cytoplasmic phosphatase(s) via their SH2 domain(s) that block signal transduction through dephosphorylation of signaling molecules. CD33 / Siglec-3 induces apoptosis in acute myeloid leukemia.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Gemtuzumab ozogamicin WAY-CMA-676; CL-555201; CMA-676; CDP-771; hP67.6-calicheamicin Approved Pfizer Inc, Ucb Sa Mylotarg EU Leukemia, Myeloid, Acute Pfizer Europe Ma Eeig 2008-01-18 Leukemia; Myelodysplastic Syndromes; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Juvenile Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Lintuzumab-gelonin conjugate Phase 1 Clinical The University Of Texas MD Anderson Cancer Center Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Myelodysplastic Syndromes; Leukemia, Myeloid, Acute Details
Anti-CD33 CAR T cell therapy (Wuhan Bio-Raid) Clinical Wuhan Bio-Raid Biotechnology Leukemia, Myeloid, Acute Details
Anti-CD33/anti-FcgammaRI bispecific antibody (UCSD) Phase 1 Clinical University Of California San Diego Leukemia, Myeloid, Acute Details
ICG-136 ICG-136; 123b-33bcCAR Phase 1 Clinical Leukemia, Myeloid, Acute Details
Anti-CD33 CAR-NK cell therapy (Sichuan Kelun-Biotech) Sichuan Kelun-Biotech Biopharmaceutical Co Ltd Details
CD33xCD3 Bispecific Antibody (Y-mAbs Therapeutics) Y-Mabs Therapeutics Inc Details
JNJ-67571244 JNJ-67571244; JNJ-67371244; JNJ-1244 Johnson & Johnson Details
OXS-3550 OXS-3550-TriKE; GTB-3550; OXS-3550; OXIS-3550; 161533-TriKE; 161533 TriKE Oxis Biotech, University Of Minnesota Details
IM73 chimeric antigen receptor T cell therapy IM-73-CAR-T Beijing Immunochina Medical Science & Technology Co Ltd Leukemia, Myeloid, Acute Details
Emerfetamab AMG-673; AMG673 Phase 1 Clinical Amgen Inc Leukemia, Myeloid, Acute Details
AL-003 AL-003 Phase 1 Clinical Abbvie Inc, Alector Alzheimer Disease Details
CLL1+CD33 CAR-T(Zhejiang University) Phase 1 Clinical Zhejiang University Leukemia, Myeloid, Acute Details
CD33 CAR-T Therapy (Zhejiang University) Phase 1 Clinical Zhejiang University Leukemia, Myeloid, Acute Details
CD33 CAR T Cells(Beijing Boren Hospital) Phase 2 Clinical Beijing Gao Boren Hospital Co Ltd Leukemia; Neoplasms; Leukemia, Myeloid, Acute Details
PRGN-3006 PRGN-3006 Phase 1 Clinical Precigen Inc Myelodysplastic Syndromes; Leukemia, Myeloid, Acute Details
Lintuzumab Ac-225/Venetoclax Phase 1 Clinical Actinium Pharmaceuticals Inc Leukemia, Promyelocytic, Acute Details
Vixtimotamab T-564; AMV-564 Phase 1 Clinical Amphivena Therapeutics Inc Solid tumours; Myelodysplastic Syndromes Details
CLL1-CD33 cCART cell therapy (iCell Gene Therapeutics) CLL1-CD33-cCAR Phase 1 Clinical Chengdu Military General Hospital Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Hematologic Neoplasms; Myelodysplastic Syndromes; Myeloproliferative Disorders; Leukemia, Myeloid, Acute Details
Lintuzumab Ac-225 (Actinium Pharmaceuticals) 225Ac-HuM-195; HuM195-Ac-225; AC225-MOAB-M195 Phase 2 Clinical Pdl Biopharma Inc Multiple Myeloma; Leukemia, Myeloid, Acute Details
BI-836858 BI-836858 Phase 2 Clinical C.H. Boehringer Sohn Ag & Co. Kg Myelodysplastic Syndromes; Leukemia, Myeloid, Acute Details
CD123-CD33 cCAR T cell therapy (iCell Gene Therapeutics) Phase 1 Clinical Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Hematologic Neoplasms; Myeloproliferative Disorders; Myelodysplastic Syndromes; Leukemia, Myeloid, Acute Details
Anti-CD33/CLL1 CAR-NK Cell Therapy Phase 1 Clinical Imbioray (Hangzhou) Biomedicine Co Ltd Leukemia, Myeloid, Acute Details
anti-CD33 CAR T cells therapy(iCell Gene Therapeutics) Phase 1 Clinical Icell Gene Therapeutics (Int'L) Ltd Hematologic Neoplasms; Leukemia, Myeloid, Acute Details
Eluvixtamab MT-114; AMG-330 Phase 1 Clinical Amgen Inc Myelodysplastic Syndromes; Leukemia, Myeloid, Acute Details
Anti-CD33/CLL-1 CAR-T (Legend) Phase 1 Clinical Legend Biotech Corp Leukemia, Promyelocytic, Acute Details
CART-33 (Chinese PLA General Hospital) Phase 2 Clinical Pla General Hospital Leukemia, Myeloid; Leukemia, Myeloid, Acute Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America: +1 800-810-0816 (Toll Free)
Asia & Pacific: +86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message